Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL
Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.
EP: 1.Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Now Viewing
EP: 2.Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL
EP: 3.R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP: 4.R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP: 5.Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL
EP: 6.An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice
EP: 7.The Future of R/R B-ALL Treatment
Related Videos
Related Content
